{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:04:18Z","timestamp":1794704658408,"version":"4.9.1"},"reference-count":116,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U01 HL143402"],"award-info":[{"award-number":["U01 HL143402"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jaccao.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:55:29Z","timestamp":1618966529000},"page":"173-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"title":["Venous and Arterial Thromboembolism in Patients With Cancer"],"prefix":"10.1016","volume":"3","author":[{"given":"Lorenzo","family":"Gervaso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloni","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2021.03.001_bib1","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1538-7836.2003.00501.x","article-title":"Malignancy, thrombosis and Trousseau: the case for an eponym","volume":"1","author":"Khorana","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and venous thromboembolic disease: a review","volume":"22","author":"Donnellan","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jaccao.2021.03.001_bib3","doi-asserted-by":"crossref","first-page":"1000.e15","DOI":"10.1016\/j.amjmed.2016.02.030","article-title":"Direct medical costs attributable to cancer-associated venous thromboembolism: a population-based longitudinal study","volume":"129","author":"Cohoon","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCULATIONAHA.111.018820","article-title":"Global variation in the relative burden of stroke and ischemic heart disease","volume":"124","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.03.001_bib5","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIR.0000000000000381","article-title":"Preventing and experiencing ischemic heart disease as a woman: state of the science: a scientific statement from the American Heart Association","volume":"133","author":"McSweeney","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.03.001_bib6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib7","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2021.03.001_bib8","first-page":"89","article-title":"Mechanism and management of cancer-associated thrombosis","volume":"72","author":"Mukai","year":"2018","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11912-019-0767-5","article-title":"Anticoagulation in cancer patients: a summary of pitfalls to avoid","volume":"21","author":"Patel","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jaccao.2021.03.001_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer","volume":"83","author":"Navi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jaccao.2021.03.001_bib11","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib12","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer\u2014a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.jaccao.2021.03.001_bib13","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0049-3848(16)30092-5","article-title":"Cancer associated thrombosis: risk factors and outcomes","volume":"140","author":"Eichinger","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaccao.2021.03.001_bib14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.seminhematol.2011.08.005","article-title":"Unusual site thrombosis","volume":"48","author":"Donadini","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib16","first-page":"e207","article-title":"Visceral thromboses in pancreas adenocarcinoma: systematic review","volume":"17","author":"Hicks","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jaccao.2021.03.001_bib17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-12-0789","article-title":"Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer","volume":"106","author":"Menapace","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib19","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.jaccao.2021.03.001_bib20","doi-asserted-by":"crossref","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","article-title":"Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines","volume":"22","author":"Mandal\u00e0","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib21","series-title":"Cancer-associated venous thromboembolic disease","year":"2020"},{"key":"10.1016\/j.jaccao.2021.03.001_bib22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2021.03.001_bib23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.2007.06973.x","article-title":"Common risk factors for both arterial and venous thrombosis","volume":"140","author":"Lowe","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib24","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib25","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2021.03.001_bib26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/rej.2013.1409","article-title":"Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer","volume":"16","author":"Vergati","year":"2013","journal-title":"Rejuvenation Res"},{"key":"10.1016\/j.jaccao.2021.03.001_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1160\/TH06-07-0365","article-title":"Racial and gender differences in the incidence of recurrent venous thromboembolism","volume":"96","author":"White","year":"2006","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.jaccao.2021.03.001_bib28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0049-3848(10)00227-6","article-title":"Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score","volume":"125","author":"Connolly","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaccao.2021.03.001_bib29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s004390100593","article-title":"Genetic risk factors of venous thrombosis","volume":"109","author":"Franco","year":"2001","journal-title":"Hum Genet"},{"key":"10.1016\/j.jaccao.2021.03.001_bib30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2021.03.001_bib31","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3324\/haematol.2012.073338","article-title":"Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study","volume":"98","author":"Dickmann","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2021.03.001_bib32","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/asheducation-2013.1.684","article-title":"Cancer-associated thrombosis","volume":"2013","author":"Connolly","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaccao.2021.03.001_bib33","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib34","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2021.03.001_bib35","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/jth.15215","article-title":"Risk of thromboembolism in patients with ALK and EGFR-mutant lung cancer: a cohort study","volume":"19","author":"Roopkumar","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.sla.0000193959.44677.48","article-title":"A\u00a0clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project","volume":"243","author":"Agnelli","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.jaccao.2021.03.001_bib37","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2021.03.001_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib39","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","article-title":"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy","volume":"100","author":"Cavo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2021.03.001_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11739-018-1828-8","article-title":"Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review","volume":"13","author":"Tamborini Permunian","year":"2018","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib41","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib42","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.medj.2021.02.002","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","volume":"2","author":"Roopkumar","year":"2012","journal-title":"Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib44","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/archinte.168.21.2377","article-title":"Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer","volume":"168","author":"Khorana","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib45","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2021.03.001_bib46","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/asheducation.V2012.1.626.3798655","article-title":"Cancer-associated thrombosis: updates and controversies","volume":"2012","author":"Khorana","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaccao.2021.03.001_bib47","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","article-title":"D-dimer and prothrombin fragment 1\u00a0+ 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study","volume":"27","author":"Ay","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib48","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2021.03.001_bib49","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1538-7836.2012.04754.x","article-title":"Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients","volume":"10","author":"Thaler","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib50","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study","volume":"102","author":"van Es","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2021.03.001_bib51","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2021.03.001_bib52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2021.03.001_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A\u00a0modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the PROTECHT score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study","volume":"22","author":"Cella","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jaccao.2021.03.001_bib55","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A\u00a0predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jaccao.2021.03.001_bib56","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A\u00a0clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib57","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib58","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jaccao.2021.03.001_bib59","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.thromres.2015.08.002","article-title":"Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis","volume":"136","author":"Lustig","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaccao.2021.03.001_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaccao.2021.03.001_bib61","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/rth2.12176","article-title":"Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting","volume":"3","author":"Kunapareddy","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib62","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1160\/TH03-03-0152","article-title":"Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures","volume":"90","author":"White","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib63","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1245\/s10434-016-5127-1","article-title":"Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis","volume":"23","author":"Fagarasanu","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib64","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.2146\/ajhp060390","article-title":"Thromboprophylaxis in medically ill patients at risk for venous thromboembolism","volume":"63","author":"Burleigh","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaccao.2021.03.001_bib65","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/bloodadvances.2020001804","article-title":"Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial","volume":"4","author":"Zwicker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2021.03.001_bib66","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A\u00a0risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score","volume":"8","author":"Barbar","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib67","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/jth.12683","article-title":"Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH","volume":"12","author":"Di Nisio","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib68","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ajh.24700","article-title":"Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool","volume":"92","author":"Patell","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib69","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib70","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11239-019-01943-5","article-title":"Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial","volume":"49","author":"Ageno","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jaccao.2021.03.001_bib72","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-153-1-201007060-00004","article-title":"Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial","volume":"153","author":"Hull","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib73","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/archinte.167.14.1471","article-title":"Venous thromboembolism in the outpatient setting","volume":"167","author":"Spencer","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib74","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jaccao.2021.03.001_bib75","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2021.03.001_bib76","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib77","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Di Nisio","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaccao.2021.03.001_bib78","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2407-8-361","article-title":"Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)","volume":"8","author":"Riess","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaccao.2021.03.001_bib79","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2021.03.001_bib80","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2021.03.001_bib81","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib82","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib83","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib84","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2021.03.001_bib85","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaccao.2021.03.001_bib86","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?","volume":"145","author":"Khorana","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaccao.2021.03.001_bib87","first-page":"428","article-title":"Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"Sabatino","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2021.03.001_bib88","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib89","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib90","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.chest.2015.10.069","article-title":"Cohort study on the management of cancer-associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured of cancer","volume":"149","author":"van der Hulle","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaccao.2021.03.001_bib91","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12\u00a0months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib92","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaccao.2021.03.001_bib93","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/0284185113491569","article-title":"Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events","volume":"55","author":"Bach","year":"2014","journal-title":"Acta Radiol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib94","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2010.03929.x","article-title":"High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients","volume":"8","author":"Singh","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094048","article-title":"Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer","volume":"9","author":"Chaturvedi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaccao.2021.03.001_bib96","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/asheducation-2017.1.121","article-title":"Incidental venous thromboembolism: is anticoagulation indicated?","volume":"2017","author":"Di Nisio","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaccao.2021.03.001_bib97","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jth.13664","article-title":"Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study","volume":"15","author":"Galanaud","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib98","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1111\/jth.13761","article-title":"Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study","volume":"15","author":"Dentali","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib99","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Subcommittee on Haemostasis and malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study","volume":"94","author":"Kopolovic","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib101","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.13713","article-title":"Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism","volume":"15","author":"Barco","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib102","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib103","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review","volume":"2","author":"Samuelson Bannow","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib104","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaccao.2021.03.001_bib105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2015.3780","article-title":"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial","volume":"313","author":"Mismetti","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2021.03.001_bib106","first-page":"119","article-title":"Postoperative venous thromboembolism and brain tumors: part I. Clinical profile","volume":"14","author":"Sawaya","year":"1992","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib107","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cncr.11623","article-title":"High incidence of thromboembolism in patients with central nervous system lymphoma","volume":"98","author":"Goldschmidt","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2021.03.001_bib108","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0959-8049(97)00167-6","article-title":"Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study","volume":"33","author":"Brandes","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2021.03.001_bib109","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/JTO.0b013e318194fad4","article-title":"Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients","volume":"4","author":"Srivastava","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib110","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2021.03.001_bib111","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2021.03.001_bib112","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ahj.2010.11.001","volume":"161","author":"Hakim","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jaccao.2021.03.001_bib113","first-page":"E202","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jaccao.2021.03.001_bib114","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.03.001_bib115","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2021.03.001_bib116","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa072100","article-title":"Coronary calcium as a predictor of coronary events in four racial or ethnic groups","volume":"358","author":"Detrano","year":"2008","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087321000715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087321000715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:53:30Z","timestamp":1762973610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087321000715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2666087321000715"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2021.03.001","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous and Arterial Thromboembolism in Patients With Cancer","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}